NTRK1 and neoplasm: Anlotinib is a novel oral multitarget receptor tyrosine kinase inhibitor that has been approved as a third-line treatment for refractory advanced non-small-cell lung cancer in light of its capacity to regulate tumor cell proliferation, apoptosis, angiogenesis, migration and invasion.